Exogene is a venture-backed biotechnology company enabling the discovery of T-cell-receptor (TCR)-based cell therapies to tackle solid tumors and reverse immune aging, by combining artificial intelligence (AI) and high-throughput TCR screening in the lab. We’re building an AI platform to computationally screen entire patient-derived TCR repertoires and identify rare, effective TCRs for cell therapy applications. Our investors include Selvedge Venture, R42 Group, KQ Labs and Entrepreneur First amongst others.